Vivani Medical
- Biotech or pharma, therapeutic R&D
Vivani Medical, a public, clinical-stage, biotechnology company (Nasdaq: VANI), is developing a pipeline of miniature, GLP-1 drug implants with annual or bi-annual dosing to treat weight management and type 2 diabetes. By leveraging the company's proprietary, platform implant technology called NanoPortal, these product candidates are designed to significantly improve medication adherence, patient tolerability, and ultimately, patient outcomes. Lead program NPM-115 (exenatide implant) is currently in the first-in-human, LIBERATE-1 study to evaluate the safety, tolerability and full pharmacokinetic profile of exenatide in obese or overweight subjects. LIBERATE-1, which also includes Bydureon and Wegovy control arms, represents the initial clinical application (and potential validation) of the NanoPortal technology. Top-Line data is expected in mid 2025. In addition, the company is also developing NPM-139 (semaglutide implant) which has the additional potential benefit of annual dosing.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}